Aspire Biopharma Holdings Inc (ASBP)

$0.38 -0.05 (-10.96%)
Market Cap 21.20M
Revenue (ttm) 0.00
Net Income (ttm) -12.54M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.73
Volume 927,700
Avg Vol 18,469,643
Day's Range N/A - N/A
Shares Out 49.53M
Stochastic %K 9%
Beta 0.74
Analysts Strong Buy
Price Target N/A

Company Profile

Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testos...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 592 7399
Address:
23150 Fashion Drive, Suite 232, Estero, United States
Pripritrading
Pripritrading Aug. 1 at 9:33 AM
$ASBP Aspire bio pharmaceutical is about to drop their latest product at the largest fitness conventions in the country on August 1-4 I’m expecting a large uptick in the stock price in the next coming days. I would get in while it’s low. Their product is an instant acting pre-workout formula that is taken sublingually. They are also using this method for aspirin, which would be a long-term investment. I have faith in this company and bought in a while ago, but we will see how all the influencers and fitness people react to their product This coming weekend.
0 · Reply
Researchpro
Researchpro Jul. 31 at 5:54 PM
$ASBP does anyone know the cash on hand for this company. I checked and could only fine $1.3M. Am I missing something ? How are they affording this big launch and a trial ?
1 · Reply
gametheory101
gametheory101 Jul. 31 at 1:15 PM
$ASBP Pretty impressive global launch across all major social media and https://www.buzzbomb.buzz/ Ordering sm after work today to try myself. Shipped internationally.
0 · Reply
Libertyhills09
Libertyhills09 Jul. 31 at 12:59 PM
$ASBP apologies to followers, it does look like the CEO Howe stepped down. i really liked his past credentials. i dont think this is a company killer, but it is a hadscratcher. stock handled it fairly well considering. lets see guys!
2 · Reply
notsurewhat
notsurewhat Jul. 31 at 12:37 PM
$ASBP https://www.stocktitan.net/news/ASBP/aspire-biopharma-holdings-inc-unveils-e-commerce-platform-launches-tftvvfzlkmrj.html
0 · Reply
notsurewhat
notsurewhat Jul. 31 at 12:37 PM
$ASBP finally a website going into fitness expo https://www.buzzbomb.buzz/
0 · Reply
allnighttom
allnighttom Jul. 31 at 12:05 PM
$ASBP Buying in today for a good weekend at the Expo
0 · Reply
gametheory101
gametheory101 Jul. 31 at 2:44 AM
$ASBP I personally invested into ASBP for these anchor leaders with stellar track records in growing unicorns from micro to billion$ cap, and in securing fda clarances - Kraig Higginson, Ernest Scheidemann, Nancy Taylor. ASBP's mgmt team remains solid after the 24July departures of new directors. Will continue dip buyings. High calculated risk, high reward. Nfa
0 · Reply
gametheory101
gametheory101 Jul. 31 at 2:35 AM
$ASBP product development is undertaken by its scientific clinical team. CEO departure, while unsettling right before major product launch, don’t necessarily signal failure. Core business - including high-dose aspirin clinical program, FDA pathway, and upcoming consumer product launches — remains on track with no reported delays. What matters: - Departed were new hires (joined 2025) not involved in product development - Core R&D engine remains - Key leaders like Kraig Higginson (since 2021) and Edward Kimball (since 2019) provide continuity. - No reported setbacks in FDA or product milestones - - F'l backings from tutes like Blackstone Leadership turnover commonly happens in early-stage biotechs. Herd-dynamic departures exist amongst buddies. Am watching the pipeline, not the fear-mongering headlines and internal power struggle, or perhaps failed remuneration negotiations given the company's already disclosed financial constraints. High calculated risk, high reward as always. Nfa
0 · Reply
RPMcMurphy702
RPMcMurphy702 Jul. 31 at 1:56 AM
$ASBP $ASPIRE Biopharma Holdings Inc Anyway you look at it the CEO jumping ship with two other board members is giant red flag. The fact that their first product is set to launch in two days is even more of a head scratcher. Something is rotten in Denmark. Could just be corporate politics, but why would people with a vested interest in this company leave right before product launch and why would a CEO quit less than two months in?? I’m no expert in these matters, and I plan to hold my shares over the weekend, but I am shocked and disappointed.
1 · Reply
Latest News on ASBP
Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement

Jul 31, 2025, 8:30 AM EDT - 1 day ago

Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement

Aspire Biopharma Holdings, Inc. Announces CEO Transition

Jul 30, 2025, 7:45 PM EDT - 1 day ago

Aspire Biopharma Holdings, Inc. Announces CEO Transition

Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

Jul 22, 2025, 10:45 AM EDT - 9 days ago

Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement

Jul 9, 2025, 8:30 AM EDT - 23 days ago

Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement

Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Jun 24, 2025, 8:30 AM EDT - 5 weeks ago

Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer

Jun 10, 2025, 8:30 AM EDT - 7 weeks ago

Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer

Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025

May 28, 2025, 8:30 AM EDT - 2 months ago

Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025

Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

May 20, 2025, 8:30 AM EDT - 2 months ago

Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21

May 8, 2025, 8:00 AM EDT - 3 months ago

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21

Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Apr 29, 2025, 8:30 AM EDT - 3 months ago

Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17

Apr 14, 2025, 8:30 AM EDT - 3 months ago

Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17

Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement

Apr 11, 2025, 8:30 AM EDT - 4 months ago

Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement

Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Apr 9, 2025, 8:30 AM EDT - 4 months ago

Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice (“GMP”) Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin

Mar 20, 2025, 8:30 AM EDT - 4 months ago

Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice (“GMP”) Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin

Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform

Mar 13, 2025, 8:30 AM EDT - 5 months ago

Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform

An Interview with the CEO: How Aspire Biopharma is Disrupting a $100 Billion Market with Sublingual Innovation

Mar 11, 2025, 8:00 AM EDT - 5 months ago

An Interview with the CEO: How Aspire Biopharma is Disrupting a $100 Billion Market with Sublingual Innovation

Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement

Mar 3, 2025, 7:30 AM EST - 5 months ago

Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement

Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin

Feb 25, 2025, 7:30 AM EST - 5 months ago

Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin

Aspire Biopharma Holdings, Inc. Announces the Execution of Securities Purchase Agreement

Feb 20, 2025, 6:15 PM EST - 5 months ago

Aspire Biopharma Holdings, Inc. Announces the Execution of Securities Purchase Agreement

Pripritrading
Pripritrading Aug. 1 at 9:33 AM
$ASBP Aspire bio pharmaceutical is about to drop their latest product at the largest fitness conventions in the country on August 1-4 I’m expecting a large uptick in the stock price in the next coming days. I would get in while it’s low. Their product is an instant acting pre-workout formula that is taken sublingually. They are also using this method for aspirin, which would be a long-term investment. I have faith in this company and bought in a while ago, but we will see how all the influencers and fitness people react to their product This coming weekend.
0 · Reply
Researchpro
Researchpro Jul. 31 at 5:54 PM
$ASBP does anyone know the cash on hand for this company. I checked and could only fine $1.3M. Am I missing something ? How are they affording this big launch and a trial ?
1 · Reply
gametheory101
gametheory101 Jul. 31 at 1:15 PM
$ASBP Pretty impressive global launch across all major social media and https://www.buzzbomb.buzz/ Ordering sm after work today to try myself. Shipped internationally.
0 · Reply
Libertyhills09
Libertyhills09 Jul. 31 at 12:59 PM
$ASBP apologies to followers, it does look like the CEO Howe stepped down. i really liked his past credentials. i dont think this is a company killer, but it is a hadscratcher. stock handled it fairly well considering. lets see guys!
2 · Reply
notsurewhat
notsurewhat Jul. 31 at 12:37 PM
$ASBP https://www.stocktitan.net/news/ASBP/aspire-biopharma-holdings-inc-unveils-e-commerce-platform-launches-tftvvfzlkmrj.html
0 · Reply
notsurewhat
notsurewhat Jul. 31 at 12:37 PM
$ASBP finally a website going into fitness expo https://www.buzzbomb.buzz/
0 · Reply
allnighttom
allnighttom Jul. 31 at 12:05 PM
$ASBP Buying in today for a good weekend at the Expo
0 · Reply
gametheory101
gametheory101 Jul. 31 at 2:44 AM
$ASBP I personally invested into ASBP for these anchor leaders with stellar track records in growing unicorns from micro to billion$ cap, and in securing fda clarances - Kraig Higginson, Ernest Scheidemann, Nancy Taylor. ASBP's mgmt team remains solid after the 24July departures of new directors. Will continue dip buyings. High calculated risk, high reward. Nfa
0 · Reply
gametheory101
gametheory101 Jul. 31 at 2:35 AM
$ASBP product development is undertaken by its scientific clinical team. CEO departure, while unsettling right before major product launch, don’t necessarily signal failure. Core business - including high-dose aspirin clinical program, FDA pathway, and upcoming consumer product launches — remains on track with no reported delays. What matters: - Departed were new hires (joined 2025) not involved in product development - Core R&D engine remains - Key leaders like Kraig Higginson (since 2021) and Edward Kimball (since 2019) provide continuity. - No reported setbacks in FDA or product milestones - - F'l backings from tutes like Blackstone Leadership turnover commonly happens in early-stage biotechs. Herd-dynamic departures exist amongst buddies. Am watching the pipeline, not the fear-mongering headlines and internal power struggle, or perhaps failed remuneration negotiations given the company's already disclosed financial constraints. High calculated risk, high reward as always. Nfa
0 · Reply
RPMcMurphy702
RPMcMurphy702 Jul. 31 at 1:56 AM
$ASBP $ASPIRE Biopharma Holdings Inc Anyway you look at it the CEO jumping ship with two other board members is giant red flag. The fact that their first product is set to launch in two days is even more of a head scratcher. Something is rotten in Denmark. Could just be corporate politics, but why would people with a vested interest in this company leave right before product launch and why would a CEO quit less than two months in?? I’m no expert in these matters, and I plan to hold my shares over the weekend, but I am shocked and disappointed.
1 · Reply
Libertyhills09
Libertyhills09 Jul. 31 at 12:18 AM
$IXHL nice run guys. check out $ASBP next. buzzbomb launch this weekend, aspirin trials underway
0 · Reply
Lifestaylaluxuryy
Lifestaylaluxuryy Jul. 30 at 7:32 PM
$ASBP Since the entire market is red, it is normal for it to fall. I will see a tighter and bigger green momentum in the coming days.
0 · Reply
Lifestaylaluxuryy
Lifestaylaluxuryy Jul. 30 at 7:31 PM
$ASBP Everything is going very well, I am holding it until the end of this year and I am expecting 200 dollars by December. I have 510,000 shares in my bag and I'm not selling them.💼💰
1 · Reply
Psikus
Psikus Jul. 30 at 5:01 PM
$ASBP Just got back. Why the 8% drop? I dont see any bad news. Thanks
3 · Reply
AtlasOG
AtlasOG Jul. 30 at 4:30 PM
$ASBP I have been distracted by other options, can someone tell me what I’ve missed here in the last 48hrs?
2 · Reply
gametheory101
gametheory101 Jul. 30 at 2:45 PM
$ASBP $ASBPW 2025 Target Pipeline (per Feb2025 roadmap): - Testosterone: Phase 1 PK studies in Q3 2025 → pre‑IND meeting in Q4 2025 → Phase 2 thereafter. - Semaglutide: Formulation nearly complete; expect FDA approval process to start in late 2025. - Migraine relief: Early studies set to begin in early Q3 2025. - Erectile dysfunction (sildenafil/tadalafil): Formulation development in Q4 2025. - Melatonin (OTC rapid‑delivery): Launch targeted for Q3 2025. - Vitamins D, E & K (OTC): Formulation expected in second half of 2025.
0 · Reply
cofhu12twits
cofhu12twits Jul. 30 at 2:25 PM
$ASBP Who is selling all these shares into the bid? Very odd orders here all morning
2 · Reply
cofhu12twits
cofhu12twits Jul. 30 at 1:36 PM
$ASBP Come on man let’s goooo!
0 · Reply
8869scy
8869scy Jul. 29 at 10:49 PM
$ASBP https://www.panabee.com/news/aspire-biopharma-issues-625-000-shares-extends-note-maturities-in-lender-settlement Would love any insight from the financially literate into this deal. Reads as bullish to me, and also will this be enough to keep Aspire from needing to further dilute stock?
1 · Reply
Psikus
Psikus Jul. 29 at 6:46 PM
$ASBP Is this a long term hold for you guys or just a short term? What do you expect it go to after the expo? Got 10,000 shares with 38% profit already, not sure if I should just take it and go or wait little bit longer. Thanks
3 · Reply
8869scy
8869scy Jul. 29 at 5:01 PM
$ASBP From the article - Booth # 401 is the first one nearest the entry doors to the convention FitExpo will publish a pre-convention media blast about BUZZ BOMB™ to over 1.8 million social media accounts including all attendees BUZZ BOMB™ will be mentioned on all signage throughout the convention, including in the lobby where patrons enter, as well as on the convention's website, newsletter, and social media postings BUZZ BOMB™ products will be in the gift bag given to every entrant (a sample pack of 4 different flavors) BUZZ BOMB is planned to be personally introduced to each influencer at the show
0 · Reply
8869scy
8869scy Jul. 28 at 5:49 PM
$ASBP https://www.stocktitan.net/news/ASBP/aspire-biopharma-holdings-inc-to-launch-its-buzz-bomb-pre-workout-btjacw2awp80.html read this, insanely bullish, just around the corner. Then next month we start the Aspirin trials
0 · Reply